Share this @internewscast.com

Key Points
  • US FDA has approved Gilead’s twice-yearly HIV prevention jab, branded as Yeztugo.
  • Lenacapavir injection proved nearly 100 per cent effective in large-scale clinical trials.
  • Gilead is planning a rapid launch in the US as well as a wider rollout of the drug in collaboration with global partners.
The US Food and Drug Administration has approved Gilead Sciences’ lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
Investors and AIDS activists had been eagerly awaiting the regulatory decision for the drug with the potential to help end the 44-year-old HIV epidemic.
The drug will be sold under the brand name Yeztugo in the US at a list price of $43,300 (US$28,218) a year.

Lenacapavir, belonging to a group of drugs called capsid inhibitors, demonstrated almost 100 percent effectiveness in preventing HIV during significant trials last year. This success has sparked new optimism about stopping the transmission of a virus that affects 1.3 million individuals annually.

Yeztugo “will only be as effective as it is accessible and affordable,” Kevin Robert Frost, CEO of the Foundation for AIDS Research, said in a statement, calling on Gilead and the US government to make sure people who want lenacapavir can get it.
Gilead said it will provide co-pay assistance for eligible insured people and that the drug may be made available free of charge under its program for the uninsured.
Medications to prevent HIV, known as pre-exposure prophylaxis or PrEP, are widely available. But most are daily pills, including low-cost generic versions of Gilead’s older drug Truvada, that require strict adherence to be effective.

Gilead said Yeztugo is priced in line with other branded drugs.

“This is a milestone moment,” said Gilead chief executive Daniel O’Day of the approval.

“We believe that lenacapavir is the most significant tool we have so far to change the course of the epidemic and eventually consign it to history,” O’Day stated.

Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global partners.
Gilead chief commercial officer Johanna Mercier said the company’s “end game” is to normalise PrEP usage, both in the United States and other countries, including low-income African nations where the virus is most prevalent.

Share this @internewscast.com
You May Also Like

Uncovering the Truth: How a Single Bone is Rewriting Australia’s Megafauna Extinction Story

A decades-old theory that First Nations peoples hunted Australia’s megafauna to extinction…
COVID-19 vaccine cancer study mrna

Groundbreaking Study Reveals mRNA COVID-19 Vaccine Potentially Extends Lifespan for Cancer Patients

COVID-19 mRNA vaccines could help cancer patients live longer by helping the…
The shopper found the Cadbury block of chocolate for sale for NZD$4.50 at a Woolworths in New Zealand

Woolworths’ Pricing Discrepancy Sparks Debate as Iconic Australian Product Found Cheaper in New Zealand

Woolworths customers in Australia have expressed frustration upon learning that a beloved…

Australia Deploys ADF Liaison Officer to Support US-Led Gaza Peace Taskforce Initiative

An official from the Australian Defence Force (ADF) will be sent to…
Trump put on 'theatre' and 'good TV' when he humiliated Rudd, senior politician says

Trump’s Dramatic Showdown: Senior Politician Reveals Behind-the-Scenes of Rudd’s Public Humiliation

Kevin Rudd was subject to two rounds of humiliation by Donald Trump…
The political future of South Australian MP Nick McBride is hanging in the balance after he was arrested and charged with assaulting his wife.

South Australian MP Faces New Assault Charges Amid Ongoing Domestic Violence Allegations

Police have laid three new charges against an independent MP who now…

Justice Delayed: Kumanjayi White’s Family Awaits Answers as Inquest Stalls

Warning: this article contains the name of an Aboriginal person who has…
Millions in the firing line of record-breaking heat

Unprecedented Heat Wave Puts Millions at Risk

Queensland is currently experiencing a severe heatwave, prompting authorities to urge residents…
People queue outside the ABC Bullion store at Martin Place, Sydney October 22, 2025.

Australian Gold Rush Turns to Bust: Prices Plummet After Record-Breaking Queues

In recent weeks, and particularly this Monday and Tuesday, people have been…
British ex-soldier acquitted of Bloody Sunday massacre murder

Former British Soldier Cleared of Murder Charges in Bloody Sunday Case

A former British paratrooper who was the only soldier ever charged in…
Western Sydney University hacked emails data breach

Major University Data Breach Exposes Sensitive Bank Accounts and Legal Information

Western Sydney University has admitted large amounts of personal data, including bank…
Hit-run victim Sally Lusted suffered a spinal fracture when she was hit by a car in Mitcham last month.

Police Hunt for Driver in Hit-and-Run Incident Leaving Woman Critically Injured

Police are searching for a hit-run driver who left a seriously injured…